Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. The company is headquartered in Andover, Massachusetts and currently employs 92 full-time employees. The company is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The firm has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. The company is also focused on developing additional OCS products for kidney transplantation.
Website: transmedics.com


  • Good financial results growth rate 165.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (83.8%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -6.7% (LTM)
  • Share price is 965.2% higher than minimum and -1.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $36.9 mln (-1.051% of cap.)

Key Financials (Download financials)

Ticker: TMDX
Share price, USD:  (+1.5%)134
year average price 75.69  


year start price 74.86 2023-05-16

min close price 36.74 2023-10-30

max close price 132.65 2024-05-06

current price 134.00 2024-05-14
Common stocks: 32 760 190

Dividend Yield:  0.0%
Last revenue growth (y/y):  131.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  134.2%
Historical growth of EBITDA:  33.3%
EV / Sales: 15.4x
Margin (EBITDA LTM / Revenue): -7.4%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 4 390
Net Debt ($m): 166
EV (Enterprise Value): 4 556
EBITDA LTM (млн $): -22
Price to Book: 31.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-05-06Zacks Investment Research

Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now?

2024-05-03Zacks Investment Research

Will TransMedics (TMDX) Gain on Rising Earnings Estimates?

2024-05-03Zacks Investment Research

TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?

2024-05-01Seeking Alpha

TransMedics Group, Inc. (TMDX) Q1 2024 Earnings Call Transcript

2024-04-30Zacks Investment Research

TransMedics (TMDX) Beats Q1 Earnings and Revenue Estimates

2024-04-26Zacks Investment Research

Exploring Analyst Estimates for TransMedics (TMDX) Q1 Earnings, Beyond Revenue and EPS

2024-04-24Zacks Investment Research

TransMedics (TMDX) Stock Sinks As Market Gains: Here's Why

2024-04-23Zacks Investment Research

TransMedics (TMDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2024-04-22Zacks Investment Research

TransMedics (TMDX) Increases Yet Falls Behind Market: What Investors Need to Know

2024-04-15Zacks Investment Research

TransMedics (TMDX) Flat As Market Sinks: What You Should Know
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TMDX TMDX TMDX TMDX TMDX TMDX TMDX
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-02 2024-02-27 2023-11-08 2023-08-04 2023-05-04 2023-02-27 2022-11-04
acceptedDate 2024-05-02 16:27:33 2024-02-27 16:15:09 2023-11-08 16:47:51 2023-08-04 16:36:53 2023-05-04 16:21:57 2023-02-27 16:17:00 2022-11-04 16:16:22
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 97M 81M 66M 52M 42M 31M 26M
costOfRevenue 37M 33M 26M 16M 13M 11M 8M
grossProfit 60M 48M 41M 37M 29M 21M 18M
grossProfitRatio 0.618 0.590 0.612 0.700 0.692 0.660 0.705
researchAndDevelopmentExpenses 11M 11M 38M 8M 6M 6M 7M
generalAndAdministrativeExpenses 36M 35M 31M 28M 25M 4M 17M
sellingAndMarketingExpenses -100 000 -1M 0 1M 0 18M 0
sellingGeneralAndAdministrativeExpenses 36M 35M 31M 29M 25M 22M 17M
otherExpenses 4M -8M 5M 2M 555 000 1M 0
operatingExpenses 47M 45M 69M 38M 31M 27M 24M
costAndExpenses 84M 79M 95M 53M 44M 38M 31M
interestIncome 0 5M 5M 2M 0 0 0
interestExpense 4M 4M 4M 3M 1M 1M 787 000
depreciationAndAmortization 4M 4M 5M 2M 555 000 1M -185 000
ebitda 17M 6M -23M 2M -2M -6M -6M
ebitdaratio 0.174 0.078 -0.351 0.029 -0.037 -0.181 -0.223
operatingIncome 12M 3M -28M -906 000 -2M -7M -6M
operatingIncomeRatio 0.128 0.032 -0.427 -0.017 -0.050 -0.216 -0.216
totalOtherIncomeExpensesNet -28 000 1M 5M 2M -536 000 78 000 -2M
incomeBeforeTax 12M 4M -27M -980 000 -3M -7M -7M
incomeBeforeTaxRatio 0.128 0.048 -0.405 -0.019 -0.063 -0.214 -0.288
incomeTaxExpense 196 000 -168 000 -2M 21 000 11 000 19 000 19 000
netIncome 12M 4M -25M -1M -3M -7M -7M
netIncomeRatio 0.126 0.050 -0.383 -0.019 -0.063 -0.214 -0.289
eps 0.370 0.120 -0.780 -0.031 -0.082 -0.210 -0.250
epsdiluted 0.350 0.120 -0.780 -0.031 -0.082 -0.210 -0.250
weightedAverageShsOut 33M 33M 33M 33M 32M 32M 30M
weightedAverageShsOutDil 35M 34M 33M 33M 32M 32M 30M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TMDX TMDX TMDX TMDX TMDX TMDX TMDX
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-02 2024-02-27 2023-11-08 2023-08-04 2023-05-04 2023-02-27 2022-11-04
acceptedDate 2024-05-02 16:27:33 2024-02-27 16:15:09 2023-11-08 16:47:51 2023-08-04 16:36:53 2023-05-04 16:21:57 2023-02-27 16:17:00 2022-11-04 16:16:22
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 350M 395M 427M 582M 195M 201M 204M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 350M 395M 427M 582M 195M 201M 204M
netReceivables 82M 64M 61M 48M 39M 28M 22M
inventory 49M 44M 39M 31M 24M 21M 19M
otherCurrentAssets 8M 8M 10M 2M 4M 3M 6M
totalCurrentAssets 488M 511M 537M 663M 262M 252M 251M
propertyPlantEquipmentNet 221M 180M 138M 27M 24M 24M 24M
goodwill 12M 12M 12M 0 0 0 0
intangibleAssets 2M 2M 2M 0 0 0 0
goodwillAndIntangibleAssets 14M 14M 14M 0 0 0 0
longTermInvestments 500 000 500 000 500 000 750 000 0 0 0
taxAssets 0 0 -500 000 0 0 0 0
otherNonCurrentAssets 85 000 62 000 560 000 59 000 1M 500 000 500 000
totalNonCurrentAssets 236M 195M 153M 28M 25M 25M 24M
otherAssets 0 0 0 0 0 0 0
totalAssets 724M 706M 689M 690M 287M 277M 275M
accountPayables 9M 13M 13M 7M 4M 3M 3M
shortTermDebt 2M 2M 2M 2M 1M 1M 1M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 2M 2M 3M 244 000 244 000 241 000 226 000
otherCurrentLiabilities 37M 38M 32M 23M 23M 19M 16M
totalCurrentLiabilities 50M 55M 49M 32M 29M 24M 21M
longTermDebt 507M 506M 514M 513M 66M 66M 66M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 7M 8M 0 0 0 0 62M
totalNonCurrentLiabilities 514M 514M 514M 513M 66M 66M 66M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 7M 8M 10M 10M 9M 9M 9M
totalLiabilities 564M 569M 563M 545M 94M 90M 87M
preferredStock 0 0 0 0 0 0 0
commonStock 651M 641M 634M 628M 674M 666M 660M
retainedEarnings -492M -504M -508M -482M -481M -479M -472M
accumulatedOtherComprehensiveIncomeLoss -182 000 -199 000 -262 000 -220 000 -218 000 -225 000 -247 000
othertotalStockholdersEquity 0 0 0 0 0 0 0
totalStockholdersEquity 159M 137M 126M 145M 193M 187M 188M
totalEquity 159M 137M 126M 145M 193M 187M 188M
totalLiabilitiesAndStockholdersEquity 724M 706M 689M 690M 287M 277M 275M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 724M 706M 689M 690M 287M 277M 275M
totalInvestments 500 000 500 000 500 000 750 000 0 0 0
totalDebt 516M 516M 516M 515M 67M 68M 68M
netDebt 166M 121M 89M -67M -128M -134M -137M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TMDX TMDX TMDX TMDX TMDX TMDX TMDX
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-02 2024-02-27 2023-11-08 2023-08-04 2023-05-04 2023-02-27 2022-11-04
acceptedDate 2024-05-02 16:27:33 2024-02-27 16:15:09 2023-11-08 16:47:51 2023-08-04 16:36:53 2023-05-04 16:21:57 2023-02-27 16:17:00 2022-11-04 16:16:22
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 12M 4M -25M -1M -3M -7M -7M
depreciationAndAmortization 4M 4M 2M 1M 1M 1M 891 000
deferredIncomeTax 0 -120 000 -1M -13 000 0 0 0
stockBasedCompensation 7M 6M 5M 5M 4M 3M 3M
changeInWorkingCapital -28M -6M -16M -12M -11M -1M -12M
accountsReceivables -18M -3M -11M -9M -11M -5M -9M
inventory -6M -7M -10M -7M -4M -2M -2M
accountsPayables -2M 416 000 3M 3M 1M 264 000 -2M
otherWorkingCapital -2M 4M 3M 2M 2M 6M 961 000
otherNonCashItems 43M 523 001 28M 719 000 160 000 -263 000 2M
netCashProvidedByOperatingActivities -3M 8M -7M -6M -9M -4M -14M
investmentsInPropertyPlantAndEquipment -44M -42M -135M -1M -927 000 -3M -3M
acquisitionsNet 0 15M -15M 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 -988 000
salesMaturitiesOfInvestments 0 0 0 0 0 107 000 29M
otherInvestingActivites 0 -42M 0 0 0 -107 000 0
netCashUsedForInvestingActivites -44M -42M -150M -1M -927 000 -3M 25M
debtRepayment 0 -393M 0 -393M 0 -36M 0
commonStockIssued 3M 924 000 2M 705 000 4M -160 000 0
commonStockRepurchased 638 000 571 000 0 0 384 000 509 000 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 3M 924 000 0 787M 0 39M 164M
netCashUsedProvidedByFinancingActivities 3M 924 000 2M 394M 4M 3M 164M
effectOfForexChangesOnCash -173 000 292 000 -177 000 5000.000 73 000 454 000 -610 000
netChangeInCash -45M -32M -155M 387M -6M -3M 174M
cashAtEndOfPeriod 350M 395M 428M 583M 196M 202M 205M
cashAtBeginningOfPeriod 395M 427M 583M 196M 202M 205M 31M
operatingCashFlow -3M 8M -7M -6M -9M -4M -14M
capitalExpenditure -44M -42M -135M -1M -927 000 -3M -3M
freeCashFlow -48M -34M -142M -7M -10M -7M -17M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-05 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-30 20:05 ET
TransMedics Reports First Quarter 2024 Financial Results
2024-04-16 20:05 ET
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
2024-04-08 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-03-19 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-28 21:06 ET
TransMedics to Present at Upcoming March Investor Conferences
2024-02-28 21:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-26 21:05 ET
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-16 21:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-12 21:05 ET
TransMedics to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
2024-01-29 20:50 ET
New Innovation-Themed Whitepaper to Debut at the February 1st Emerald Groundhog Day Investment Forum
2024-01-22 15:30 ET
Investment Opportunities in the Innovation Economy Headline the 2024 Emerald Groundhog Day Investment Forum
2024-01-16 21:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-12-18 21:05 ET
TransMedics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 21:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-11-14 21:05 ET
TransMedics to Present at the Piper Sandler 35th Annual Healthcare Conference
2023-11-06 21:05 ET
TransMedics Reports Third Quarter 2023 Financial Results
2023-11-03 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-10-23 20:05 ET
TransMedics to Report Third Quarter 2023 Financial Results on November 6, 2023
2023-10-10 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-08-28 20:05 ET
TransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-16 20:05 ET
TransMedics Completes Acquisition of Summit Aviation
2023-08-07 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-08-03 20:05 ET
TransMedics Reports Second Quarter 2023 Financial Results
2023-08-02 21:28 ET
Bridge to Life Divests Certain Assets to TransMedics
2023-08-02 21:00 ET
TransMedics Acquires Warm Perfusion EVOSS™ and Cold Perfusion LifeCradle® Technologies from Bridge to Life
2023-08-01 15:00 ET
TransMedics Signs Definitive Agreement to Acquire Summit Aviation to Expand TransMedics Aviation Capabilities for Organ Transplantation
2023-07-26 21:09 ET
TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary
2023-07-26 20:05 ET
TransMedics to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-07-20 20:05 ET
TransMedics to Report Second Quarter 2023 Financial Results on August 3, 2023
2023-05-30 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-05-09 03:21 ET
TransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028
2023-05-08 11:23 ET
TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028
2023-05-01 20:05 ET
TransMedics Reports First Quarter 2023 Financial Results
2023-05-01 12:00 ET
TransMedics Releases Inaugural Environmental, Social & Governance (ESG) Report
2023-04-17 20:05 ET
TransMedics to Report First Quarter 2023 Financial Results on May 1, 2023
2023-02-24 21:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-02-22 21:09 ET
TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-21 21:05 ET
TransMedics to Present at Upcoming March Investor Conferences
2023-02-08 21:05 ET
TransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
2023-02-02 21:08 ET
TransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations
2022-12-21 21:05 ET
TransMedics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
2022-11-07 21:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-11-03 20:05 ET
TransMedics Reports Third Quarter 2022 Financial Results
2022-10-20 20:05 ET
TransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022
2022-08-29 20:05 ET
TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-05 00:19 ET
TransMedics Announces Upsize and Pricing of Public Offering of Common Stock
2022-08-03 20:36 ET
TransMedics Announces Proposed Public Offering of Common Stock
2022-08-01 20:05 ET
TransMedics Reports Second Quarter 2022 Financial Results
2022-07-26 20:05 ET
TransMedics to Present at the Canaccord Genuity 42nd Annual Growth Conference
2022-07-18 20:05 ET
TransMedics to Report Second Quarter 2022 Financial Results on August 1, 2022
2022-06-03 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-05-03 20:05 ET
TransMedics Reports First Quarter 2022 Financial Results
2022-04-28 11:00 ET
TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication
2022-04-21 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-04-19 22:04 ET
TransMedics to Report First Quarter 2022 Financial Results on May 3, 2022
2022-04-19 20:05 ET
TransMedics Announces the Presentation of New OCS™ Heart and OCS™ Lung Clinical Data at the International Society of Heart and Lung Transplantation 2022 Annual Meeting
2022-03-01 21:05 ET
TransMedics to Present at the Oppenheimer's 32nd Annual Healthcare Conference
2022-02-25 21:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-02-23 21:05 ET
TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-22 21:05 ET
TransMedics to Present at the Cowen 42nd Annual Healthcare Conference
2022-02-09 21:05 ET
TransMedics to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
2022-01-05 23:41 ET
TransMedics Announces Publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery
2021-12-22 12:00 ET
TransMedics to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-11-11 21:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-11-09 21:05 ET
TransMedics Reports Third Quarter 2021 Financial Results
2021-11-04 20:05 ET
TransMedics to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
2021-11-04 11:00 ET
TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial
2021-10-26 20:05 ET
TransMedics to Report Third Quarter 2021 Financial Results on November 9, 2021
2021-09-29 11:00 ET
TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transplantation
2021-09-07 11:00 ET
TransMedics Receives FDA Approval for its OCS Heart System Enabling Broader Utilization of Donor Hearts for Transplantation in the U.S.­
2021-08-26 20:05 ET
TransMedics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-09 20:05 ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-08-05 20:05 ET
TransMedics Reports Second Quarter 2021 Financial Results
2021-07-29 22:20 ET
TransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs
2021-07-28 20:05 ET
TransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference
2021-07-22 20:05 ET
TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021
2021-07-15 01:00 ET
TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System
2021-07-14 11:05 ET
TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Liver System
2021-06-10 14:35 ET
TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting
2021-06-08 20:05 ET
TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Choice Award for Most Impactful Presentation at the American Transplant Congress (ATC 2021)
2021-05-04 20:01 ET
TransMedics Reports First Quarter 2021 Financial Results
2021-04-20 20:05 ET
TransMedics to Report First Quarter 2021 Financial Results on May 4, 2021
2021-04-07 02:20 ET
TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System
2021-04-06 11:05 ET
TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Heart System
2021-03-02 21:01 ET
TransMedics Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-01 21:15 ET
TransMedics Announces Scheduling of OCS Heart FDA Advisory Committee Meeting
2021-02-16 21:05 ET
TransMedics to Present at the Cowen 41st Annual Healthcare Conference
2021-02-16 21:01 ET
TransMedics to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021
2020-12-24 13:00 ET
TransMedics to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-23 21:01 ET
TransMedics Appoints Merilee Raines to Board of Directors
2020-11-04 21:01 ET
TransMedics Reports Third Quarter 2020 Financial Results
2020-10-29 20:02 ET
TransMedics to Participate in Upcoming Virtual Investor Conferences
2020-10-21 20:01 ET
TransMedics to Report Third Quarter 2020 Financial Results on November 4, 2020
2020-09-28 20:05 ET
TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting
2020-09-01 20:30 ET
TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference
2020-08-05 20:01 ET
TransMedics Reports Second Quarter 2020 Financial Results
2020-07-28 20:01 ET
TransMedics to Present at the Canaccord 40th Annual Growth Conference
2020-07-23 12:00 ET
TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020
2020-05-26 22:49 ET
TransMedics Announces Pricing of Public Offering of Common Stock
2020-05-26 11:14 ET
TransMedics Announces Proposed Public Offering of Common Stock
2020-05-26 11:09 ET
TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS™ Liver PROTECT Trial
2020-05-06 20:05 ET
TransMedics Reports First Quarter 2020 Financial Results
2020-04-23 20:05 ET
TransMedics to Report First Quarter 2020 Financial Results on May 6, 2020
2020-04-13 20:05 ET
TransMedics Provides COVID-19 Pandemic Update and Announces Preliminary Financial Results for First Quarter 2020
2020-03-17 11:00 ET
TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting Due to COVID-19 Emergency
2020-03-02 21:05 ET
TransMedics Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-20 21:05 ET
TransMedics to Present at the Cowen 40th Annual Health Care Conference
2020-02-19 21:05 ET
TransMedics to Report Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020
2019-12-19 13:00 ET
TransMedics to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-04 13:00 ET
TransMedics’ Organ Care System (OCS™) Technology Used in First U.S. Adult Human Heart Transplants From DCD Donors
2019-11-06 12:30 ET
TransMedics Reports Third Quarter 2019 Financial Results
2019-10-23 20:05 ET
TransMedics Announces Change to Time of Third Quarter 2019 Earnings Conference Call on Wednesday, November 6
2019-10-16 20:05 ET
TransMedics to Report Third Quarter 2019 Financial Results on November 6, 2019

SEC forms

Show financial reports only

SEC form 10
2024-05-02 00:00 ET
TransMedics Group published news for 2024 q1
SEC form 8
2024-04-30 16:31 ET
TransMedics Group published news for 2024 q1
SEC form 8
2024-04-30 16:31 ET
TransMedics Group reported for 2024 q1
SEC form 10
2024-02-27 16:15 ET
TransMedics Group published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
TransMedics Group published news for 2023 q4
SEC form 8
2024-02-26 16:19 ET
TransMedics Group published news for 2023 q4
SEC form 8
2024-02-26 16:19 ET
TransMedics Group reported for 2023 q4
SEC form 10
2023-11-08 00:00 ET
TransMedics Group published news for 2023 q3
SEC form 8
2023-11-06 16:23 ET
TransMedics Group reported for 2023 q3
SEC form 10
2023-08-04 16:36 ET
TransMedics Group published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
TransMedics Group published news for 2023 q2
SEC form 6
2023-08-03 16:29 ET
TransMedics Group reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
TransMedics Group published news for 2023 q2
SEC form 6
2023-06-29 16:05 ET
TransMedics Group published news for 2023 q1
SEC form 6
2023-06-07 16:30 ET
TransMedics Group published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
TransMedics Group published news for 2023 q1
SEC form 8
2023-05-01 00:00 ET
TransMedics Group published news for 2023 q1
SEC form 10
2023-02-27 16:17 ET
TransMedics Group reported for 2022 q4
SEC form 10
2023-02-27 00:00 ET
TransMedics Group reported for 2022 q4
SEC form 6
2023-02-24 16:31 ET
TransMedics Group published news for 2022 q4
SEC form 6
2023-02-22 16:16 ET
TransMedics Group published news for 2022 q4
SEC form 8
2023-02-22 00:00 ET
TransMedics Group reported for 2022 q4
SEC form 6
2023-02-02 17:49 ET
TransMedics Group published news for 2022 q4
SEC form 6
2022-11-04 16:31 ET
TransMedics Group published news for 2022 q3
SEC form 10
2022-11-04 16:16 ET
TransMedics Group reported for 2022 q3
SEC form 10
2022-11-04 00:00 ET
TransMedics Group reported for 2022 q3
SEC form 6
2022-11-03 16:16 ET
TransMedics Group published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
TransMedics Group reported for 2022 q3
SEC form 6
2022-08-08 08:52 ET
TransMedics Group published news for 2022 q2
SEC form 10
2022-08-03 16:07 ET
TransMedics Group reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
TransMedics Group reported for 2022 q2
SEC form 6
2022-08-01 16:15 ET
TransMedics Group published news for 2022 q2
SEC form 8
2022-08-01 00:00 ET
TransMedics Group reported for 2022 q2
SEC form 6
2022-07-29 16:16 ET
TransMedics Group published news for 2022 q2
SEC form 6
2022-06-02 16:30 ET
TransMedics Group published news for 2022 q1
SEC form 10
2022-05-05 16:16 ET
TransMedics Group reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
TransMedics Group reported for 2022 q1
SEC form 6
2022-05-03 16:15 ET
TransMedics Group published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
TransMedics Group reported for 2022 q1
SEC form 6
2022-04-20 16:02 ET
TransMedics Group published news for 2022 q1
SEC form 10
2022-03-01 16:16 ET
TransMedics Group published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
TransMedics Group published news for 2021 q4
SEC form 6
2022-02-23 16:16 ET
TransMedics Group published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
TransMedics Group published news for 2021 q4
SEC form 10
2021-11-09 17:00 ET
TransMedics Group published news for 2021 q3
SEC form 6
2021-11-09 16:16 ET
TransMedics Group published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
TransMedics Group published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
TransMedics Group published news for 2021 q3
SEC form 6
2021-09-29 07:15 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-09-07 07:39 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-08-09 07:26 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-08-06 17:03 ET
TransMedics Group published news for 2021 q2
SEC form 10
2021-08-06 16:16 ET
TransMedics Group published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-08-05 16:28 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-07-15 06:07 ET
TransMedics Group published news for 2021 q2
SEC form 6
2021-05-28 16:05 ET
TransMedics Group published news for 2021 q1
SEC form 10
2021-05-07 06:01 ET
TransMedics Group published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
TransMedics Group published news for 2021 q1
SEC form 6
2021-05-04 16:15 ET
TransMedics Group published news for 2021 q1
SEC form 6
2021-04-16 16:10 ET
TransMedics Group published news for 2021 q1
SEC form 6
2021-04-07 06:07 ET
TransMedics Group published news for 2021 q1
SEC form 6
2021-03-24 18:45 ET
TransMedics Group published news for 2020 q4
SEC form 6
2021-03-24 16:31 ET
TransMedics Group published news for 2020 q4
SEC form 10
2021-03-11 16:19 ET
TransMedics Group published news for 2020 q4
SEC form 6
2021-03-02 16:15 ET
TransMedics Group published news for 2020 q4
SEC form 6
2021-01-05 17:51 ET
TransMedics Group published news for 2020 q4
SEC form 6
2020-12-23 16:12 ET
TransMedics Group published news for 2020 q3
SEC form 10
2020-11-06 16:07 ET
TransMedics Group published news for 2020 q3
SEC form 6
2020-11-04 16:08 ET
TransMedics Group published news for 2020 q3